Literature DB >> 33276546

Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma.

Jennifer E Agrusa1, Brooks P Scull1, Harshal A Abhyankar1, Howard Lin1, Nmazuo W Ozuah1, Rikhia Chakraborty1, Olive S Eckstein1, Nitya Gulati1, Elmoataz Abdel Fattah1, Nader K El-Mallawany1, Rayne H Rouce1, ZoAnn E Dreyer1, Julienne Brackett1, Judith F Margolin1, Joseph Lubega1, Terzah M Horton1, Catherine M Bollard2, M Monica Gramatges1, Kala Y Kamdar1, Kenneth L McClain1, Tsz-Kwong Man1, Carl E Allen1.   

Abstract

Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed-Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected by the levels of inflammatory cytokines or chemokines in pre-therapy plasma of children with HL. The study objectives were to better define the inflammatory pre-therapy plasma proteome and identify plasma biomarkers associated with extent of disease and clinical outcomes in pediatric HL. Pre-therapy plasma samples were obtained from pediatric subjects with newly diagnosed HL and healthy pediatric controls. Plasma concentrations of 135 cytokines/chemokines were measured with the Luminex platform. Associations between protein concentration and disease characteristics were determined using multivariate permutation tests with false discovery control. Fifty-six subjects with HL (mean age: 13 years, range 3-18) and 47 controls were analyzed. The cytokine/chemokine profiles of subjects with HL were distinct from controls, and unique cytokines/chemokines were associated with high-risk disease (IL-10, TNF-α, IFN-γ, IL-8) and slow early response (CCL13, IFN-λ1, IL-8). TNFSF10 was significantly elevated among those who ultimately relapsed and was significantly associated with worse event-free survival. These biomarkers could be incorporated into biologically based risk stratification to optimize outcomes and minimize toxicities in pediatric HL.

Entities:  

Keywords:  Hodgkin lymphoma; chemokines; childhood hematological malignancies; cytokines; immunology

Year:  2020        PMID: 33276546      PMCID: PMC7761312          DOI: 10.3390/cancers12123603

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  50 in total

1.  CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.

Authors:  C Blanpain; I Migeotte; B Lee; J Vakili; B J Doranz; C Govaerts; G Vassart; R W Doms; M Parmentier
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

2.  Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Janina Kaminska; Jan Walewski
Journal:  Med Oncol       Date:  2011-06-30       Impact factor: 3.064

3.  Immunoenzymatic assessment of interferon-gamma in Hodgkin and Sternberg-Reed cells.

Authors:  J Gerdes; C Kretschmer; G Zahn; M Ernst; D B Jones; H D Flad
Journal:  Cytokine       Date:  1990-07       Impact factor: 3.861

4.  Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22.

Authors:  Marijke Niens; Lydia Visser; Ilja M Nolte; Gerrit van der Steege; Arjan Diepstra; Pablo Cordano; Ruth F Jarrett; Gerard J Te Meerman; Sibrand Poppema; Anke van den Berg
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

5.  Serum VEGF as a significant marker of treatment response in hodgkin lymphoma.

Authors:  M Weyl Ben Arush; A Ben Barak; S Maurice; E Livne
Journal:  Pediatr Hematol Oncol       Date:  2007-03       Impact factor: 1.969

6.  Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

Review 7.  Current status of prognostication in classical Hodgkin lymphoma.

Authors:  Girish Venkataraman; M Kamran Mirza; Dennis A Eichenauer; Volker Diehl
Journal:  Br J Haematol       Date:  2014-02-04       Impact factor: 6.998

Review 8.  Interferon-gamma: an overview of signals, mechanisms and functions.

Authors:  Kate Schroder; Paul J Hertzog; Timothy Ravasi; David A Hume
Journal:  J Leukoc Biol       Date:  2003-10-02       Impact factor: 4.962

9.  Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis.

Authors:  Fang Wang; Lingxiao Xu; Xiaoke Feng; Dunming Guo; Wenfeng Tan; Miaojia Zhang
Journal:  Arthritis Res Ther       Date:  2012-10-19       Impact factor: 5.156

Review 10.  Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.

Authors:  Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-10-11
View more
  2 in total

1.  Quantitative Plasma Proteomics to Identify Candidate Biomarkers of Relapse in Pediatric/Adolescent Hodgkin Lymphoma.

Authors:  Ombretta Repetto; Laura Caggiari; Mariangela De Zorzi; Caterina Elia; Lara Mussolin; Salvatore Buffardi; Marta Pillon; Paola Muggeo; Tommaso Casini; Agostino Steffan; Christine Mauz-Körholz; Maurizio Mascarin; Valli De Re
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

2.  Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.

Authors:  Zhixing Kuang; Xun Li; Rongqiang Liu; Shaoxing Chen; Jiannan Tu
Journal:  Front Cell Dev Biol       Date:  2021-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.